For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Placebo Group | Placebo was normal saline | None | None | 1 | 38 | 15 | 38 | View |
| Aminocaproic Acid Group | Aminocaproic acid is an antifibrinolytic drug | None | None | 1 | 37 | 11 | 37 | View |
| HOE 140 Group | Bradykinin B2 receptor antagonist | None | None | 1 | 40 | 18 | 40 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Re-exploration for bleeding | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Acute kidney injury | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| New onset postoperative atrial fibrillation | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Placement of permanent pacemaker | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Prolonged Mechanical Ventilation (>24 hours) | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |